Erschienen in:
01.04.2010 | Editorial
Rifaximin and Crohn’s Disease: A New Solution to an Old Problem?
verfasst von:
A. S. Day, R. B. Gearry
Erschienen in:
Digestive Diseases and Sciences
|
Ausgabe 4/2010
Einloggen, um Zugang zu erhalten
Excerpt
It is clear that the intestinal flora, and interactions between these flora and the host, contribute strongly to the pathogenesis of Crohn’s disease (CD). Modification of the intestinal flora by various modalities has been explored in animal models of gut inflammation and in the human setting. In this issue, Shafran and Burgunder [
1] illustrate the outcomes of the use of rifaximin, a non-absorbable antibiotic, in the setting of CD. This report incorporated the retrospective analysis of rifaximin use in 68 adults with active CD. These individuals were treated with rifaximin for a median of 16.6 weeks, with almost all treated with 600 mg daily. Overall, two-thirds of these patients were noted to enter remission with rifaximin therapy. …